

Ismail Elalamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6977421/publications.pdf>

Version: 2024-02-01

149
papers

4,125
citations

186265

28
h-index

123424

61
g-index

159
all docs

159
docs citations

159
times ranked

6921
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematological findings and complications of COVID-19. American Journal of Hematology, 2020, 95, 834-847.	4.1	1,354
2	Editor's Choice "European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery, 2021, 61, 9-82.	1.5	308
3	Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thrombosis and Haemostasis, 2020, 120, 937-948.	3.4	294
4	A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS "Cancer-Associated Thrombosis Study. Oncologist, 2017, 22, 1222-1231.	3.7	167
5	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thrombosis and Haemostasis, 2020, 120, 1597-1628.	3.4	131
6	<i>In vitro</i> aspirin resistance detected by PFA ¹⁰⁰ TM closure time: pivotal role of plasma von Willebrand factor. British Journal of Haematology, 2004, 124, 80-85.	2.5	102
7	Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up. European Respiratory Journal, 2021, 58, 2003677.	6.7	95
8	2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group. Critical Reviews in Oncology/Hematology, 2010, 73, 31-46.	4.4	78
9	Cryofibrinogenemia: New Insights into Clinical and Pathogenic Features. American Journal of Medicine, 2009, 122, 1128-1135.	1.5	73
10	The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thrombosis and Haemostasis, 2012, 107, 1044-1052.	3.4	63
11	Calpastatin Controls Polymicrobial Sepsis by Limiting Procoagulant Microparticle Release. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 744-755.	5.6	56
12	MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thrombosis and Haemostasis, 2013, 110, 844-851.	3.4	52
13	Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thrombosis and Haemostasis, 2004, 91, 531-537.	3.4	50
14	The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thrombosis and Haemostasis, 2004, 91, 977-985.	3.4	50
15	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 982-991.	3.4	50
16	Evidence for cAMP-dependent Platelet Ectoprotein Kinase Activity That Phosphorylates Platelet Glycoprotein IV (CD36). Journal of Biological Chemistry, 1996, 271, 24776-24780.	3.4	48
17	Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagulation and Fibrinolysis, 2004, 15, 149-156.	1.0	41
18	Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. International Journal of Hematology, 2010, 92, 296-301.	1.6	41

#	ARTICLE	IF	CITATIONS
19	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. Thrombosis and Haemostasis, 2020, 120, 1680-1690.	3.4	38
20	Screening for aspirin resistance in stable coronary artery patients by three different tests. Thrombosis Research, 2007, 121, 413-418.	1.7	37
21	Tissue factor over-expression by human pancreatic cancer cells BXP3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thrombosis Research, 2012, 129, 779-786.	1.7	37
22	Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thrombosis Research, 2012, 129, 101-103.	1.7	36
23	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. Oncologist, 2018, 23, 1372-1381.	3.7	36
24	Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: Confirmation in a prospective study. Platelets, 2013, 24, 441-447.	2.3	33
25	In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thrombosis and Haemostasis, 2004, 92, 1296-1302.	3.4	32
26	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Therapeutics and Clinical Risk Management, 2014, 10, 423.	2.0	30
27	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. Thrombosis and Haemostasis, 2020, 120, 132-140.	3.4	30
28	Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. Thrombosis and Haemostasis, 2020, 120, 1096-1107.	3.4	29
29	Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. British Journal of Haematology, 2003, 123, 327-334.	2.5	28
30	Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia. Thrombosis Research, 2009, 124, 554-559.	1.7	28
31	TNF- α , inefficient by itself, potentiates IL-1 β -induced PGHS-2 expression in human pulmonary microvascular endothelial cells: requirement of NF- κ B and p38 MAPK pathways. British Journal of Pharmacology, 2002, 136, 1005-1014.	5.4	24
32	Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome. Obstetrics, Gynecology and Reproduction, 2020, 14, 123-131.	0.5	24
33	Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?. Supportive Care in Cancer, 2008, 16, 1333-1341.	2.2	23
34	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer Journal, 2018, 8, 102.	6.2	23
35	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007.	3.4	21
36	In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thrombosis Research, 2008, 121, 493-497.	1.7	20

#	ARTICLE	IF	CITATIONS
37	The GPIIb/IIIa polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. <i>Thrombosis Research</i> , 2010, 125, e265-e268.	1.7	19
38	Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. <i>TH Open</i> , 2021, 05, e376-e386.	1.4	18
39	Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma. <i>Thrombosis Research</i> , 2013, 132, 584-591.	1.7	17
40	Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era. <i>Thrombosis Research</i> , 2021, 198, 19-22.	1.7	17
41	Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. <i>Thrombosis and Haemostasis</i> , 2009, 102, 42-48.	3.4	16
42	The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement. <i>Thrombosis Research</i> , 2013, 132, 685-691.	1.7	16
43	Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. <i>Cancers</i> , 2019, 11, 48.	3.7	16
44	Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers. <i>Obstetrics, Gynecology and Reproduction</i> , 2020, 14, 132-147.	0.5	16
45	Heparin-Induced Thrombocytopenia: An Estimate of the Average Cost in the Hospital Setting in France. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 428-434.	1.7	15
46	Cancer cells BXP3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. <i>Thrombosis Research</i> , 2015, 136, 1273-1279.	1.7	15
47	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. <i>Thrombosis Journal</i> , 2019, 17, 6.	2.1	15
48	Heparin-induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1959-1972.	3.8	14
49	Prevalence and Patient Profile in Activated Protein C Resistance. <i>American Journal of Clinical Pathology</i> , 1995, 104, 450-454.	0.7	13
50	Heparin-induced skin necrosis: HIT-2 without thrombocytopenia. <i>Intensive Care Medicine</i> , 2011, 37, 172-173.	8.2	13
51	Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 191, S50-S57.	1.7	13
52	Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 696-707.	2.3	12
53	The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile. <i>Thrombosis and Haemostasis</i> , 2006, 95, 822-8.	3.4	12
54	JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis. <i>Thrombosis Research</i> , 2008, 122, 427-428.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2020, 95, E18-E20.	4.1	11
56	COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice. <i>Journal of Perinatal Medicine</i> , 2020, 48, 985-994.	1.4	11
57	COVID-19, septic shock and syndrome of disseminated intravascular coagulation syndrome. Part 1. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 0, , .	0.6	11
58	Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease. <i>Thrombosis Research</i> , 2009, 123, 640-643.	1.7	10
59	Platelet glycoprotein IIIa (platelet antigen 1/platelet antigen 2) polymorphism and 1-year outcome in patients with stable coronary artery disease. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 674-678.	1.0	9
60	Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI. <i>TH Open</i> , 2019, 03, e309-e315.	1.4	9
61	Effect of Low Molecular Weight Heparins and Fondaparinux Upon Thrombin Generation Triggered by Human Pancreatic Cancer Cells BXPC3. <i>Current Vascular Pharmacology</i> , 2014, 12, 893-902.	1.7	9
62	Prospective Evaluation of a Rapid Functional Assay for Heparin-Induced Thrombocytopenia Diagnosis in Critically Ill Patients*. <i>Critical Care Medicine</i> , 2019, 47, 353-359.	0.9	8
63	Extracellular neutrophil traps (NETs) in the pathogenesis of thrombosis and thromboinflammation. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 75-85.	0.6	8
64	Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 499-514.	0.5	8
65	COVID-19, hemostasis disorders and risk of thrombotic complications. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020, 75, 306-317.	0.6	8
66	Venous thrombosis risk factors in pregnant women. <i>Journal of Perinatal Medicine</i> , 2022, 50, 505-518.	1.4	8
67	In vitro effect of melagatran and lepirudin on clot-bound thrombin. <i>Thrombosis Research</i> , 2003, 110, 249-252.	1.7	7
68	On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 633-638.	1.0	7
69	Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 108-113.	2.1	7
70	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs – A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e438-e448.	1.4	7
71	Description of Response to Aspirin and Clopidogrel in Outpatients With Coronary Artery Disease Using Multiple Electrode Impedance Aggregometry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 356-363.	1.7	6
72	Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process. <i>TH Open</i> , 2019, 03, e340-e347.	1.4	6

#	ARTICLE	IF	CITATIONS
73	Pathogenic heparin-induced thrombocytopenia and thrombosis (HIT) antibodies determined by rapid functional flow cytometry. <i>European Journal of Haematology</i> , 2019, 103, 225-233.	2.2	6
74	Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells. <i>Thrombosis Research</i> , 2020, 187, 170-179.	1.7	6
75	COVID-19, septic shock and syndrome of disseminated intravascular coagulation syndrome. Part 2. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 0, , .	0.6	6
76	Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty. , 1998, 45, 329-331.		5
77	The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 155-163.	1.7	5
78	Novel coronavirus infection (COVID-19) and risk groups in obstetrics and gynecology. <i>Obstetrics, Gynecology and Reproduction</i> , 2020, 14, 159-162.	0.5	5
79	Comparison of Seven Generic Enoxaparins with Lovenox® on In Vitro Cross-Reactivity with Antibodies From Heparin Induced Thrombocytopenia.. <i>Blood</i> , 2010, 116, 1105-1105.	1.4	5
80	Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood. <i>Thrombosis and Haemostasis</i> , 2007, 97, 109-18.	3.4	5
81	Does Lipid Profile Affect Thrombin Generation During Ramadan Fasting in Patients With Cardiovascular Risks?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 980-986.	1.7	4
82	Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network. <i>Journal of Onco-Nephrology</i> , 2018, 2, 37-49.	0.6	4
83	Signal transduction involved in the platelet adenylate cyclase sensitization associated with PGH 2 /TxA 2 receptor desensitization. <i>British Journal of Haematology</i> , 1997, 99, 190-196.	2.5	3
84	Endothelial cell markers' kinetics following umbilical cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 2209-2212.	1.3	3
85	Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. <i>American Journal of Hematology</i> , 2016, 91, E455-6.	4.1	3
86	Transplantation Outcome in Recipients Engrafted With Organs Recovered From the First French Deceased Donor With a SARS-COV-2 Vaccine-induced Thrombotic Thrombocytopenia. <i>Transplantation</i> , 2021, 105, e84-e86.	1.0	3
87	Anticoagulant, anti-inflammatory, antiviral and antitumor properties of heparins. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 295-312.	0.5	3
88	Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays. <i>Blood</i> , 2016, 128, 5020-5020.	1.4	3
89	Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets. <i>Thrombosis Research</i> , 1997, 86, 255-262.	1.7	2
90	Graft Product for Autologous Peripheral Blood Stem Cell Transplantation Enhances Thrombin Generation and Expresses Procoagulant Microparticles and Tissue Factor. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 684-690.	1.7	2

#	ARTICLE	IF	CITATIONS
91	Thrombin Generation Profile in Patients With Steady State Peripheral Arterial Disease. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 193-194.	1.7	2
92	Steady State Sickle Cell Anemia Is Associated with Increased Formation of Erythrocyte-Derived Microparticles and Acceleration of Thrombin Generation.. Blood, 2009, 114, 4001-4001.	1.4	2
93	Distinct Roles Of Antithrombin-Dependent Antithrombotic Agents (Lovenox, Fondaparinux) and Direct Anti-Xa Anti-Coagulant (Apixaban) On The Inhibition Of Thrombin Generation Induced By Human Pancreatic (BXPC3) and Human Breast (MCF7) Cells. Blood, 2013, 122, 3632-3632.	1.4	2
94	The Cost of Hospitalization for Thromboembolic Events in Patients with Colon or Lung Cancer. Blood, 2014, 124, 3515-3515.	1.4	2
95	Venous thrombosis risk factors in pregnant women. Journal of Perinatal Medicine, 2020, .	1.4	2
96	Risk Factors in Cancer Patients. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 465-475.	0.6	2
97	Anticoagulants: dose control methods and inhibitors. Obstetrics, Gynecology and Reproduction, 2022, 16, 158-175.	0.5	2
98	Effect of two oral doses of 17Î²â€œestradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized doubleâ€œblind placeboâ€œcontrolled study. Fundamental and Clinical Pharmacology, 2010, 24, 239-245.	1.9	1
99	Unusual Case of HIT With Cardiac Arrest During Hemodialysis. Annals of Pharmacotherapy, 2014, 48, 1086-1089.	1.9	1
100	Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients. European Journal of Emergency Medicine, 2019, 26, 230-231.	1.1	1
101	Clinical significance of measuring ADAMTS-13, its inhibitor and von Willebrand factor in obstetric and gynecological practice. Obstetrics, Gynecology and Reproduction, 2021, 15, 93-106.	0.5	1
102	Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962098346.	1.7	1
103	Inhibition of In Vitro Thrombin Generation: Another Parameter Reinforcing the LMWH Heterogeneity.. Blood, 2005, 106, 912-912.	1.4	1
104	Prevalence of Risk Factors for VTE In Hospitalized Medical and Surgical Patients. Data From the Comparison of Methods for Thromboembolic Risk Assessment with Clinical Perceptions and AwareneSS In Real Life Surgical and Medical Patients (COMPASS) Study. Blood, 2010, 116, 3337-3337.	1.4	1
105	Thrombotic microangiopathy in cancer patients. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 323-332.	0.6	1
106	Disseminated intravascular coagulation in perinatal medicine. Obstetrics, Gynecology and Reproduction, 2020, 14, 56-68.	0.5	1
107	Vaccine-induced immune thrombotic thrombocytopenia: definition, risks with different vaccines, and regulatory responses. Obstetrics, Gynecology and Reproduction, 2021, 15, 562-575.	0.5	1
108	Impact of LMWH and Specific Factor Xa Inhibitors, Apixaban and Fondaparinux, on Cancer Cell Biology and Procoagulant Properties of Cancer Microenvironment. Blood, 2021, 138, 2136-2136.	1.4	1

#	ARTICLE	IF	CITATIONS
109	The Compass-COVID19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. <i>Blood</i> , 2021, 138, 2121-2121.	1.4	1
110	Features of the novel coronavirus infection in cancer patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 15, 726-737.	0.5	1
111	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. <i>Hemato</i> , 2022, 3, 188-203.	0.6	1
112	Platelets, thrombo-inflammation and cancer. <i>Obstetrics, Gynecology and Reproduction</i> , 2022, 15, 755-776.	0.5	1
113	Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210979.	1.7	1
114	C0398 Does buffy coat prepared for autologous stem cell transplantation in cancer patients has procoagulant properties? An in vitro study. <i>Thrombosis Research</i> , 2012, 130, S166-S167.	1.7	0
115	Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 697-704.	1.7	0
116	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy Na ⁺ ve Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAT-CAT-MM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S235-S236.	0.4	0
117	The Effect of Various Types of Anticoagulant Therapy on the Reduction of Mortality in COVID-19. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 268-278.	0.6	0
118	Features of nervous system damage in antiphospholipid syndrome. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 404-414.	0.5	0
119	Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110339.	1.7	0
120	Circulating Platelet-Leukocyte Aggregates as a Marker of Microvascular Lesions in Diabetic Patients.. <i>Blood</i> , 2005, 106, 3965-3965.	1.4	0
121	In Vitro Effect of Danaparoid Sodium (Orgaran [®]) on Thrombin Generation after Minimal Tissue Factor Pathway Activation.. <i>Blood</i> , 2005, 106, 4151-4151.	1.4	0
122	Differential Procoagulant Phenotype of Pancreatic and Breast Cancer Cells Related to Different Tissue Factor Activity.. <i>Blood</i> , 2007, 110, 3992-3992.	1.4	0
123	Platelets and Heparin Induced Thrombocytopenia Antibodies Do Not Influence the Inhibitory Activity of Argatroban on Thrombin Generation.. <i>Blood</i> , 2007, 110, 929-929.	1.4	0
124	Endothelial Cell Markers Kinetics Following Umbilical Cord Blood Transplantation in Adults.. <i>Blood</i> , 2007, 110, 4964-4964.	1.4	0
125	Platelet Microparticle Generation Assay: a Valuable and Simpler Alternative to 14C-SRA for Type-II HIT Diagnosis.. <i>Blood</i> , 2010, 116, 1442-1442.	1.4	0
126	Structural Determinants of Enoxaparin Oligosaccharides for the Down-Regulation of Tissue Factor Induced Factor VIIa Generation In Human Plasma.. <i>Blood</i> , 2010, 116, 1106-1106.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs. Blood, 2010, 116, 3334-3334.	1.4	0
128	The Effects of Hydroxyurea on the Thrombin Generation and Microparticles in Sickle Cell Anemia Patients. Blood, 2011, 118, 2292-2292.	1.4	0
129	Hypercoagulability Linked to Breast Cancer Depends On the Stage and the Duration of the Tumor Evolution. Blood, 2012, 120, 3396-3396.	1.4	0
130	A Novel Test for the Rapid Rule Out of Heparin-Induced Thrombocytopenia Diagnosis in Intensive Care unit patients. Blood, 2012, 120, 1119-1119.	1.4	0
131	In Vitro Evaluation of the Procoagulant Properties of Autologous Peripheral Blood Stem Cell Transplant. Blood, 2012, 120, 1134-1134.	1.4	0
132	Markers of Hypercoagulability in Breast Cancer: What Is Their Clinical Relevance?. Blood, 2012, 120, 5133-5133.	1.4	0
133	A Synthetic Evaluation Of Genetic and Pharmacological Resistance To Clopidogrel and On Treatment Residual Platelet Aggregation In Patients With Atherothrombosis. Blood, 2013, 122, 3631-3631.	1.4	0
134	Impact Of Thrombin Generation, Tissue Factor Activity and Thrombomodulin Activity On The Positivity Of Assisted Reproductive Technique In Infertile Women. Blood, 2013, 122, 3630-3630.	1.4	0
135	Use of Thrombin Generation Assay As Tool for the Evaluation of the Antithrombotic Sameness of Enoxaparine Copies. Blood, 2014, 124, 5092-5092.	1.4	0
136	The Impacts of Thromboembolic Events in Breast and Prostate Cancer Patients: Incidence, Hospitalization Duration and Costs. Blood, 2014, 124, 4828-4828.	1.4	0
137	Differential Influence of Lung Cancer Stage, Time from Diagnosis and Chemotherapy on Plasma and Cellular Biomarkers of Hypercoagulability. the Roadmap Study. Blood, 2014, 124, 4253-4253.	1.4	0
138	Acquisition of Resistance to Doxorubicin By Breast Cancer Cells MCF7 Enhances Their Procoagulant Properties and Alters the Efficacy of Antithrombotic Agents to Inhibit Thrombin Generation. Blood, 2015, 126, 1113-1113.	1.4	0
139	Thrombosis in Cancer Patients during Hospitalization: Impact on Stays and Costs. Blood, 2015, 126, 4487-4487.	1.4	0
140	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. Blood, 2015, 126, 1074-1074.	1.4	0
141	A Clinic-Genetic Score for Risk Assessment of Recurrent Venous Thrombo Embolism. Blood, 2016, 128, 1428-1428.	1.4	0
142	Idarucizumab, a Specific Antidote for Dabigatran, Cross-React with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds. Blood, 2016, 128, 3836-3836.	1.4	0
143	Easily Performed Functional Flow Cytometry Assay for Heparin-Induced Thrombocytopenia and Thrombosis (HIT): Correlation with Clinical Presentation, Immunoassay and Serotonin-Release Assay. Blood, 2016, 128, 2601-2601.	1.4	0
144	In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study. Blood, 2018, 132, 2014-2014.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study. Blood, 2019, 134, 2425-2425.	1.4	0
146	Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study. Blood, 2019, 134, 1913-1913.	1.4	0
147	Analysis of Inter-Observer Agreement of Adjudication of Colors of Pad Colors of Doac Dipstick to Determine Presence or Absence of Direct Oral Anticoagulants in Outpatients' Urine Samples. Blood, 2021, 138, 3213-3213.	1.4	0
148	Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study. Blood, 2021, 138, 3207-3207.	1.4	0
149	The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. Hemato, 2022, 3, 204-218.	0.6	0